Fitusiran
Oligonucleotide
Overview
Fitusiran is a oligonucleotide active pharmaceutical ingredient (ChEMBL CHEMBL4297754).
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Fitusiran expires 7 Dec 2036 and exclusivity 28 Mar 2032. Generic API sourcing typically opens up once these lapse.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.